BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27922696)

  • 1. Down syndrome critical region 1 positively correlates with angiogenesis in hypopharyngeal cancer.
    Lv C; Liu D; Wei X
    Mol Med Rep; 2017 Jan; 15(1):263-270. PubMed ID: 27922696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the expression of integrin β1, VEGF and MVD in hypopharyngeal squamous cell carcinoma.
    Hong YM; Gan WG; Xu ZH
    Genet Mol Res; 2014 Aug; 13(3):6455-65. PubMed ID: 25158264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
    Shin J; Lee JC; Baek KH
    Cancer Lett; 2014 Jan; 342(1):70-81. PubMed ID: 24051307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of expression and significance of DSCR1 gene in laryngopharynx cancer and peri-cancerous tissues].
    Lü C; Pan X; Gao J; Li Z
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Sep; 25(18):848-50. PubMed ID: 22256743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis and the expression of vascular endothelial growth factors A and C in squamous cell carcinoma of the piriform fossa.
    Homer JJ; Prentice MG; Cawkwell L; Birchall M; Greenman J; Stafford ND
    Arch Otolaryngol Head Neck Surg; 2003 Oct; 129(10):1110-4. PubMed ID: 14568798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway.
    Qin L; Zhao D; Liu X; Nagy JA; Hoang MV; Brown LF; Dvorak HF; Zeng H
    Mol Cancer Res; 2006 Nov; 4(11):811-20. PubMed ID: 17114339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The expression difference of VEGF, PDGF/dThdPase and MVD on primary hypopharyngeal carcinoma and metastasis lymph nodes].
    Dong P; Yoshimi M; Tadashi N
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Sep; 16(9):451-3. PubMed ID: 15515527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis.
    Gollogly LK; Ryeom SW; Yoon SS
    J Surg Res; 2007 Sep; 142(1):129-36. PubMed ID: 17610901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel transcriptional complex on the VE-cadherin promoter regulated the downregulation of VE-cadherin in the Down Syndrome Candidate Region 1 isoform 1L-mediated angiogenesis.
    Hou S; Niu G; Liu X; Bourbon PM; Zhang D; Cui P; Zhao K; Zhao D; Zeng H
    Microvasc Res; 2021 Nov; 138():104209. PubMed ID: 34146582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy.
    Zhang SC; Miyamoto S; Kamijo T; Hayashi R; Hasebe T; Ishii G; Fukayama M; Ochiai A
    Jpn J Clin Oncol; 2003 Dec; 33(12):613-9. PubMed ID: 14769838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of metastin/a G-protein-coupled receptor signaling and Down syndrome critical region 1 in epithelial ovarian cancer.
    Hata K; Watanabe Y; Nakai H; Minami T; Ohsaki H; Hirakawa E; Hoshiai H
    Anticancer Res; 2009 Feb; 29(2):617-23. PubMed ID: 19331211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down Syndrome Candidate Region 1 Isoform 1L regulated tumor growth by targeting both angiogenesis and tumor cells.
    Chen C; Cui P; Zhao K; Niu G; Hou S; Zhao D; Zeng H
    Microvasc Res; 2022 Mar; 140():104305. PubMed ID: 34958805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?
    Yao YG; Duh EJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):648-56. PubMed ID: 15358155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma.
    Miyahara M; Tanuma J; Sugihara K; Semba I
    Cancer; 2007 Sep; 110(6):1287-94. PubMed ID: 17674352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression.
    Shang ZJ; Li JR
    J Oral Pathol Med; 2005 Mar; 34(3):134-9. PubMed ID: 15689226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
    Miyata Y; Kanda S; Ohba K; Nomata K; Hayashida Y; Eguchi J; Hayashi T; Kanetake H
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):800-6. PubMed ID: 16467091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
    Ryeom S; Baek KH; Rioth MJ; Lynch RC; Zaslavsky A; Birsner A; Yoon SS; McKeon F
    Cancer Cell; 2008 May; 13(5):420-31. PubMed ID: 18455125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression level of vascular endothelial growth factor-C and -A in cultured human oral squamous cell carcinoma correlates respectively with lymphatic metastasis and angiogenesis when transplanted into nude mouse oral cavity.
    Nakazato T; Shingaki S; Kitamura N; Saito C; Kuwano R; Tachibana M
    Oncol Rep; 2006 Apr; 15(4):825-30. PubMed ID: 16525666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression difference between cancers of the larynx and hypopharynx is not due to tumor size and vascularization.
    Lukits J; Timár J; Juhász A; Döme B; Paku S; Répássy G
    Otolaryngol Head Neck Surg; 2001 Jul; 125(1):18-22. PubMed ID: 11458208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.